Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Renal Cell × montanide ISA 51 × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 5 Uveal Melanoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Accelerated Phase 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 32 Nivolumab 32 Bevacizumab 10 Ipilimumab 9 Sunitinib 8 aldesleukin 7 Interleukin-2 7 lenvatinib 6 cabozantinib 6 Paclitaxel 6 Everolimus 6 Cyclosporine 6 Axitinib 6 fludarabine phosphate 5 Radiotherapy 5 Peripheral Blood Stem Cell Transplantation 5 Mycophenolic Acid 5 Docetaxel 5 Cyclophosphamide 5 belzutifan 4 Whole-Body Irradiation 4 Sorafenib 4 Radiosurgery 4 Interferon-alpha 4 Cetuximab 4 fludarabine 3 durvalumab 3 cemiplimab 3 avelumab 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02429440 2017-08-17

UroRCC

University Hospital Tuebingen

Phase 1/2 Unknown

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡